Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,712 | $2,531 | $2,202 | $1,999 |
| - Cash | $282 | $228 | $212 | $223 |
| + Debt | $317 | $319 | $317 | $318 |
| Enterprise Value | $3,747 | $2,621 | $2,308 | $2,094 |
| Revenue | $133 | $128 | $112 | $99 |
| % Growth | 4.1% | 14.5% | 12.2% | – |
| Gross Profit | $107 | $104 | $89 | $77 |
| % Margin | 80.8% | 81.7% | 79.4% | 77.1% |
| EBITDA | $9 | $4 | -$4 | -$15 |
| % Margin | 6.8% | 3.3% | -3.6% | -14.8% |
| Net Income | $3 | -$6 | -$15 | -$24 |
| % Margin | 2.2% | -4.6% | -13.2% | -23.9% |
| EPS Diluted | 0.05 | -0.12 | -0.3 | -0.49 |
| % Growth | 141.7% | 60% | 38.8% | – |
| Operating Cash Flow | $40 | $12 | -$2 | -$5 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $39 | $12 | -$2 | -$5 |